| Literature DB >> 32246125 |
María Dolores Casaña-Ruiz1, Carlos Bellot-Arcís1, Vanessa Paredes-Gallardo1, Verónica García-Sanz2, José Manuel Almerich-Silla1, José María Montiel-Company1.
Abstract
The reason of the biological stability loss of mini-implants is still a matter of discussion between dentistry professionals. The main objective of this systematic literature review and meta-analysis was to analyze the risk factors that prejudice this loss. A search was made in the electronic databases Pubmed, Scopus, Embase and Cochrane, in addition a manual search was made too in Grey Literature (Opengrey). No limits were set on the year of publication or language. The inclusion criteria were: studies in humans treated with fixed appliances with mini-implants, where the risk factors for secondary stability were evaluated for a minimum of 8 weeks. After eliminating duplicate studies and assessing which ones achieve the inclusion criteria, a total of 26 studies were selected for the qualitative synthesis, 18 of them were included in the quantitative synthesis. Common risk variables were compared in all of them. Analyzing the forest and funnel plots, statistically significant differences were obtained only for location, the upper maxilla having lower risk than the mandible with an odds ratio of 0.56 and confidence interval of 0.39 to 0.80. Prospective studies under controlled conditions should be required in order to obtain a correct assessment of the variables analyzed.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32246125 PMCID: PMC7125198 DOI: 10.1038/s41598-020-62838-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Records excluded and reasons for exclusion.
| RECORDS EXCLUDED | ARTICLES EXCLUDED, WITH REASONS |
|---|---|
| Männchen | |
| Ji | |
| Tsoudis | |
| Reynders | |
| Antoszewska | |
| Schätzle | |
| Schätzle | |
| Kim | |
| Papadopoulus | |
| Min | |
| Consolaro | |
| Kuroda | |
| Rodriguez | |
| Dalesandri | |
| Romano | |
| Uribe | |
| Cornelis | |
| Papadopoulus | |
| Sarul | |
| Lin | |
| Liu | |
| Kim | |
| Leo | |
| Hong | |
| Yi | |
| Afrashtehfer | |
| Yi | |
| Alharbi | |
| Mohammed | |
| Lyczek | |
| Azeem | |
| Azeem | |
| Kakali | |
| Ichsnoke |
Study data. Analyzed variables: study design, diameter, length, patient, age, total number of TADs, position, number of success TADs, definition of success and definition of failure.
| AUTHOR YEAR | STUDY DESIGN | DIAMETER (MM) | LENGTH (MM) | PATIENT (N) | AGE | N° of TAD | POSITION | N° of SUCCESS | DEFINITION OF SUCCESS | DEFINITION OF FAILURE |
|---|---|---|---|---|---|---|---|---|---|---|
| Miyawaki | Retrospective | 1.0 /1.5/2.3 | 6 / 11/ 14 | 51 | 21.8+_ 7.8 | 134 | Upper jaw. 63 Lower jaw. 61 | 103 | NA | Diameter 1 mm or less, inflammation periimplant tissue, high mandibular plane. |
| Chen | Prospective | 2.0 | 5/7/9/11/13/15 | 44 | 29 _+ 8.9 | 140 | Upper jaw. 105 Lower jaw. 35 | 125 | Absence of inflammation and clinical movement. | NA |
| Park | Retrospective | 1.2/ 1.2/ 1.2/ 2 | 5/ 6,8,10/ 4,6,8,10/ 10,12,14,15 | 87 | 15.5 _+ 8.3 | 227 | Upper jaw. 124 Lower jaw. 103 | 208 | Keep until the final of the treatment. Try to remove. | Lost during the treatment. |
| Chen | Retrospective | 2/ 2/ 1.2 | 5–9/ 5–21/ 4–10 | 129 | 24.5 | 359 | Upper jaw x. 263 Lower jaw. 96 | 306 | Enough stability during the treatment. | Lost during the treatment. |
| Wiechmann | Prospective | 1.1 /1.6 | 5/ 6/ 7/ 8/ 10 | 49 | 26.9 _+ 8.9 | 133 | Upper jaw. 88 Lower jaw. 45 | 102 | Absence of inflammation and clinical movement. | NA |
| Kuroda | Retrospective | 1.3/ 2.0/ 2.3 | 6 /7/ 8/ 10/ 11/ 12 | 75 | 21.8 _+ 8.2 | 79 | Upper jaw. 156 Lower jaw. 60 | 70 | Steady during one year. | NA |
| Chen | Retrospective | 2.0 | 5–9/ 8–14 | 194 | 25.1 | 489 | Upper jaw. 399 Lower jaw. 90 | 445 | NA | Lost during the treatment. |
| Moon | Retrospective | 1.6 | 8 | 209 | 20.3 | 480 | Upper jaw. 279 Lower jaw 0.201 | 402 | Absence of mobility after 8 month. | NA |
| Wu | Retrospective | 1.1–1.5/ 1.7/ 2.0 | 7/ 8/ 10/ 11/ 12/ 13/ 14/ 15 | 166 | 26.5_+ 8.9 | 414 | Upper jaw. 268 Lower jaw. 135 | 372 | NA | Lost after 8 month, or fractured after the insertion. |
| Viwattanatipa | Prospective | 1.2 | 8/ 10/ 12 | 49 | 23.2 | 97 | Upper jaw. 97 Lower jaw. 0 | 65 | NA | Mobility, displacement or infection. |
| Motoyoshi | Retrospective | 1.6 | 8 | 52 | 26.1_+ 8.4 | 109 | Upper jaw. 42 Lower jaw. 67 | 103 | No mobility, no lost during the treatment. | NA |
| Lee | Prospective | 1.8 | 8.5 | 141 | 27 | 260 | Upper jaw. 260 Lower jaw. 0 | 238 | NA | NA |
| Moon | Retrospective | 1.6 | 8 | 306 | 14.45_+ 2.64 23.73_+ 2.70 37.04_+ 7.26 | 778 | NA | 614 | Steady during one year. | NA |
| Manni | Retrospective | 1.5/ 1.3 | 9/ 11 | 132 | 25.9 | 300 | Upper jaw. 427 Lower jaw. 351 | 243 | Absence of inflammation or loss. | Inflammation and instability. |
| Takaki | Retrospective | NA | NA | 455 | 25.7 _+ 9.8 | 904 | Upper jaw. 265 Lower jaw. 639 | 842 | NA | Mobility or loss of the implant. |
| Sharma | Retrospective | 1.3 | 8 | 73 | 22.45 | 139 | Upper jaw. 97 Lower jaw. 42 | 122 | Absence of inflammation and clinical movement. Keep until the final of the treatment | Spontaneous loss, severe mobility, replacement, infection, pain, pathology of soft tissue. |
| Topouzelis | Retrospective | 1.2/ 1.4 | 8/ 10 | 34 | 27.2_+ 7.3 | 82 | Upper jaw. 62 Lower jaw. 20 | 74 | Absence of inflammation, pain or mobility. | Infección or mobility. Instability with orthodontics forces. |
| Kim | Retrospective | 1.6 | 6/ 8 | 286 | 10–30 | 429 | Upper jaw. 357 Lower jaw. 72 | 332 | NA | Mobility or loss after 6 months. |
| Dobranski | Prospective | 1.6/ 1.8 | 6/8/10 | 166 | 25.8 | 293 | Upper jaw. 259 Lower jaw. 34 | 256 | NA | Loss of stability. |
| Yao | Retrospective | NA | NA | 220 | 29.3 | 727 | Upper jaw. 412 Lower jaw.231 | 643 | NA | Mobility or loss during the treatment. |
| Melo | Retrospective | 1.3/ 1.4/ 1.6 | 5/ 7/ 9/ 11 | 570 | 42.7 | 1356 | Upper jaw. 816 Lower jaw. 539 | 1208 | NA | Clinical mobility or o fracture during the insertion. |
| Jing | Retrospective | 1.4/ 2.0 | 6/ 8/ 10 | 114 | 19.26_+ 9.19 | 253 | Upper jaw. 170 Lower jaw. 83 | 224 | Keep until the success. | NA |
| Lee | Retrospective | 1.2/ 1.3 | 8 | 71 | 19.2_+ 6.63 | 127 | NA | 108 | Keep the insertion in the bone with success during one year. | NA |
| Tsai | Prospective | 1.5/2 | 8/9/10/11/12 | 139 | 25,7 + − 7,5 | 254 | Upper jaw. 213 Lower jaw. 41 | 218 | NA | NA |
| Aly | Prospective | 1.5/1.6/1.8 | 6/8710 | 82 | 21.41 | 180 | Upper jaw. 52 Lower jaw. 128 | 148 | Being functionally stable until the end of the treatment with no signs of inflammation or any pathological condition around the TAD site, and anchorage function sustained until the end of the purpose | Sudden spontaneous loss or the presence of mobility or looseness during routine visits that required replacing the TAD used, or infected painful pathological condition that could be seen as normal inflammation. |
| Park | Retrospective | 1.2/ 1.3 | 8 | 80 | 17.95_+ 6.13 | 160 | NA | 136 | Keep the insertion in the bone with success during one year. |
MM: millimeters; N: number of total patients; TAD: temporary anchorage device; NA: not applicable.
Quality assessment. Newcastle-Ottawa scale[10].
| Author. Year | Selection | Comparability | Outcome | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5a | 5b | 6 | 7 | 8 | ||
| Miyawaki | * | NA | * | * | * | * | * | * | 7/9 | |
| Chen | * | NA | * | * | * | * | * | * | 7/9 | |
| Park | * | NA | * | * | * | * | * | * | 7/9 | |
| Chen | * | NA | * | * | * | * | * | * | 7/9 | |
| Wiechmann | * | NA | * | * | * | * | * | * | 7/9 | |
| Kuroda | * | NA | * | * | * | * | * | * | 7/9 | |
| Chen | * | NA | * | * | * | * | * | * | 7/9 | |
| Moon | * | NA | * | * | * | * | * | * | 7/9 | |
| Wu | * | NA | * | * | * | * | * | 6/9 | ||
| Motoyoshi | * | NA | * | * | * | * | * | * | 7/9 | |
| Viwattanatipa | * | NA | * | * | * | * | * | * | 7/9 | |
| Lee | * | NA | * | * | * | * | * | * | 7/9 | |
| Takaki | * | NA | * | * | * | * | * | 6/9 | ||
| Moon | * | NA | * | * | * | * | * | * | 7/9 | |
| Manni | * | NA | * | * | * | * | * | * | 7/9 | |
| Sharma | * | NA | * | * | * | * | * | 6/9 | ||
| Topouzelis | * | NA | * | * | * | * | * | * | 7/9 | |
| Kim | * | NA | * | * | * | * | * | * | 7/9 | |
| Dobranski | * | NA | * | * | * | * | * | * | 7/9 | |
| Yao | * | NA | * | * | * | * | * | * | 7/9 | |
| Melo | * | NA | * | * | * | * | * | * | 7/9 | |
| Jing | * | NA | * | * | * | * | * | * | 7/9 | |
| Lee | * | NA | * | * | * | * | * | * | 7/9 | |
| Tsai | * | NA | * | * | * | * | * | * | 7/9 | |
| Aly | * | NA | * | * | * | * | * | * | 7/9 | |
| Park | * | NA | * | * | * | * | * | * | 7/9 | |
Figure 1The PRISMA flow diagram[8].
Risk factors and event rate.
| Risk Factor | EVENT RATE (%) | IC 95%LOWER LIMIT | UPPER LIMIT | Q-VALUE | P-VALUE | I2 (%) | N TOTAL | NUMBER OF STUDIES INCLUDIED |
|---|---|---|---|---|---|---|---|---|
| <30 yr-old | 19.7 | 12.9 | 28.8 | 219.5 | <0.001 | 96.4 | 2934 | 8 |
| Lower jaw | 18.8 | 14.2 | 24.5 | 105,7 | <0.001 | 87.7 | 2433 | 14 |
| Length > 8 mm | 18.6 | 8.4 | 36.4 | 36.2 | <0.001 | 88.9 | 729 | 5 |
| Right side | 17.3 | 12.7 | 23.0 | 23.2 | 0.001 | 74.1 | 930 | 7 |
| Anterior | 15.7 | 9.4 | 25.1 | 24.6 | <0.001 | 87.8 | 653 | 3 |
| Women | 15.5 | 12.6 | 18.9 | 123.9 | <0.001 | 87.1 | 4541 | 16 |
| Diameter > 1.4 mm | 15.3 | 10.1 | 22.5 | 26.1 | <0.001 | 84.7 | 1591 | 5 |
| Ridge | 15.1 | 10 | 22.3 | 6.655 | 0.248 | 24.87 | 258 | 6 |
| Men | 15.0 | 12.0 | 18.5 | 63.9 | <0.001 | 74.9 | 1715 | 16 |
| Length < 8 mm | 13.6 | 9.6 | 18.9 | 13.5 | 0.009 | 70.3 | 1239 | 5 |
| Left side | 13.4 | 9.5 | 18.7 | 22.4 | 0.001 | 73.2 | 920 | 7 |
| Palate | 13.4 | 9.8 | 18 | 13.2 | 0.068 | 46.8 | 600 | 7 |
| Vestibular | 12.5 | 10.3 | 15.0 | 24.1 | 0.001 | 70.9 | 2544 | 7 |
| Posterior | 12.1 | 7.8 | 18.3 | 6.7 | 0.080 | 55.6 | 618 | 3 |
| Upper jaw | 11.4 | 9.1 | 14.4 | 65.4 | 0.000 | 80.1 | 3550 | 14 |
| Diameter < 1.4 mm | 10.8 | 8.9 | 12.9 | 0.111 | 0.991 | 0.000 | 912 | 4 |
| >30 yr-old | 9.5 | 7.4 | 12.3 | 10.4 | 0.234 | 23.5 | 755 | 8 |
Figure 2Forest and funnel plots for meta-analyses for: gender, age, mini-implant length and mini-implant diameter.
Figure 3Forest and funnel plots for meta-analyses for different mini-implant locations.